Abstract

Objective To investigate the expression of BRCA1 in familial thyroid cancer (FTC) and the relationship between BRCA1 expression and clinicopathologic features. Methods The expression of BRCA1 protein and mRNA was detected respectively by immunohistochemistry and RT-PCR in 37 FTC tissues, 35 sporadic thyroid carcinoma tissues and 35 normal thyroid tissues. Results BRCA1 mRNA expression was significantly downregulated in FTC (0.210±0.025) compared with sporadic thyroid carcinoma (0.943±0.021) and normal thyroid tissues (1.001±0.087) (P<0.01) . The positive rate of BRCA1 protein expression was significantly lower in FTC (56.8%, 21/37) than that in sporadic thyroid carcinoma (85.7%, 30/35) and normal thyroid tissues (94.5%, 33/35) (P<0.05) . There was a correlation between BRCA1 protein expression and FTC clinicopathologic features (P<0.05) . FTC patients with lower BRCA1 protein expression tended to have higher risk for bilateral carcinoma, lymph node metastasis, capsular invasion, morbidity under 30 years old and more than 2 patients in a family. Conclusions The expression of BRCA1 protein and mRNA is downregulated in FTC. BRCA1 protein might serve as a potential biomarker for predicating biological behavior and prognosis of FTC. Key words: BRCA1; Thyroid carcinoma; Familial

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.